AB Science (ABSCF) announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using its lead compound masitinib, based on preclinical data. This new US paten ensures intellectual property protection for masitinib until November 2040.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential